Biological variation of cardiovascular risk factors in patients with diabetes

Diabetic Medicine

Volumn 30, Issue 10, 2013, Pages 1172-1180

  Dawson, A J ^a   Sathyapalan, T ^a   Atkin, S L ^a   Kilpatrick, E S ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMLODIPINE; ATORVASTATIN; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; ISOPROSTANE DERIVATIVE; LACIDIPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTAGLANDIN F2 ALPHA; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TRIACYLGLYCEROL;

AMERICAN INDIAN; AREA UNDER THE CURVE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE VARIABILITY; BLOOD VESSEL INJURY; CAPILLARY BLOOD; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; COMPARATIVE STUDY; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN RESISTANCE; INTENSIVE CARE; INTERVENTION STUDY; KIDNEY CONCENTRATING CAPACITY; MEAN ARTERIAL PRESSURE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; POPULATION RESEARCH; POSTMENOPAUSE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84884705711     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12160     Document Type: Review

References (58)

1. Fraser CG. Biological Variation: From Principles to Practice. Washington DC: AACC Press, 2001.
2. Westgard QC. Desirable Specifications for Total Error, Imprecision, and Bias, Derived from Intra- and Inter-Individual Biological Variation. 2012. Available at www.westgard.com/biodatabase1.htm Last accessed 16 October 2012.
3. Lacher DA, Hughes JP, Carroll MD. Estimate of biological variation of laboratory analytes based on the third national health and nutrition examination survey. Clin Chem 2005; 51: 450-452.
4. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010; 31: 171-182.
5. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010; 38: 838-842.
6. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009; 11: 551-565.
7. Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009; 11: 623-633.
8. Kilpatrick ES, Rigby AS, Atkin SL. For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med 2010; 27: 868-871.
9. Ceriello A, Ihnat MA. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 2010; 27: 862-867.
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
11. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997; 96: 1750-1754.
12. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-1354.
13. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 2006; 295: 1681-1687.
14. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008; 51: 183-190.
15. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010; 53: 562-571.
16. Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract 2010; 89: 296-302.
17. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-1490.
18. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009; 52: 2229-2232.
19. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001; 44: 1215-1220.
20. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009; 16: 113-118.
21. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008; 31: 2198-2202.
22. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
23. 1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia 2012; 55: 2128-2131.
24. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 1259-1264.
25. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 2007; 56: 1913-1921.
26. Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160: 1160-1168.
27. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes. Diabetes Care 2002; 25: 2022-2025.
28. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 2002; 87: 1560-1562.
29. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003; 362: 1211-1224.
30. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412-419.
31. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
32. Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care 2010; 33: 2442-2447.
33. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-2581.
34. Tsalamandris C, Panagiotopoulos S, Allen TJ, Waldrip L, Van Gaal B, Goodall I et al. Long-term intraindividual variability of serum lipids in patients with type I and type II diabetes. J Diabetes Complications 1998; 12: 208-214.
35. Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009; 58: 2649-2655.
36. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-791.
37. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007; 167: 1545-1551.
38. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 1999; 22: 394-398.
39. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 2006; 29: 363-367.
40. Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 1974; 23: 449-453.
41. Rohlfing C, Wiedmeyer HM, Little R, Grotz VL, Tennill A, England J et al. Biological variation of glycohemoglobin. Clin Chem 2002; 48: 1116-1118.
42. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998; 21: 261-264.
43. Braga F, Dolci A, Mosca A, Panteghini M. Biological variability of glycated hemoglobin. Clin Chim Acta 2010; 411: 1606-1610.
44. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30: 2453-2457.
45. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2008; 31: 1991-1996.
46. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
47. Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A et al. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 2008; 25: 326-332.
48. Lepore G, Corsi A, Dodesini AR, Nosari I, Trevisan R. Continuous subcutaneous insulin infusion is better than multiple daily insulin injections in reducing glucose variability only in type 1 diabetes with good metabolic control. Diabetes Care 2010; 33: e81.
49. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther 2009; 11: 339-344.
50. Sathyapalan T, Atkin SL, Kilpatrick ES. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabet Med 2008; 25: 909-915.
51. Frattola A, Parati G, Castiglioni P, Paleari F, Ulian L, Rovaris G et al. Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension 2000; 36: 622-628.
52. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007; 50: 181-188.
53. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
54. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964.
55. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.
56. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407.
57. Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001; 358: 1026-1027.
58. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-915.